TY - JOUR
T1 - Clinical studies of arbekacin sulfate in the pediatric field
AU - Fujii, Ryochi
AU - Fujita, Kouzou
AU - Sakata, Yohko
AU - Abe, Toshiaki
AU - Tajima, Takeshi
AU - Terashima, Itaru
AU - Meguro, Hidenori
AU - Watanabe, Nobuo
AU - Mikuni, Ken Ichi
AU - Sakai, Tadasu
AU - Kasai, Noriaki
AU - Sunakawa, Keisuke
AU - Iwata, Satoshi
AU - Satoh, Yoshitake
AU - Akita, Hironobu
AU - Toyonaga, Yoshikiyo
AU - Ishihara, Toshihide
AU - Nakamura, Hironori
AU - Iwai, Naoichi
AU - Nakamura, Haruhi
AU - Kuno, Kuniyoshi
AU - Kamiya, Hitoshi
AU - Kitamura, Kenji
AU - Inoue, Masakazu
AU - Nishi, Hideaki
AU - Nishimura, Tadafumi
AU - Sugita, Kumiko
AU - Takagi, Michio
AU - Aoki, Shigeyuki
AU - Kobayashi, Yohnosuke
AU - Higashino, Hirohiko
AU - Kobayashi, Yutaka
AU - Haruta, Tsunekazu
AU - Kurashige, Takanobu
AU - Tomoda, Takashi
AU - Motohiro, Takashi
AU - Hirata, Tomoshige
AU - Aramaki, Masafumi
AU - Ono, Eiichiro
AU - Hashimoto, Nobuo
AU - Tominaga, Kaoru
AU - Tsuji, Yoshio
AU - Hayashi, Katsutoshi
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1994
Y1 - 1994
N2 - A clinical investigation was carried out to evaluate arbekacin, an aminoglycoside, in the treatment of MRS A infections (pneumonia, septicemia, etc.) of pediatric patients. the obtained results are summarized as follows. 1. Clinical results: Excluding those patients who met the present exclusion criteria and withdrawal cases from a total of 18 patients, 10 patients (3, 6, and 1 cases of septicemia, pneumonia, and urinary tract infection, respectively) were subjected to clinical evaluation. These were composed of 1, 1, 6, and 2 cases of neonate, infants, pre- and school age children, respectively. Excellent, good and fair results were obtained in 5, 2, and 3 patients, respectively; thus, the efficacy rate was 70.0%. the efficacy rate by disease was 100%, 50.0% and 100% in septicemia, pneumonia, and urinary tract infection, respectively. the bacteriological eradications were obtained in 70.0% of the total patients; by disease, these rates were 100% and 50.0% in septicemia/urinary tract infection and in pneumonia, respectively. the MIC50 as well as the MIC80 against MRS A strains isolated from 9 patients were 0.39 μg/ml and 1.56μg/ml, respectively. No adverse reactions were observed in the 15 patients, while in laboratory test values, one case each out of 12 patients examined showed 7-GTP elevation, proteinuria, and hematuria. 2. Pharmacokinetics: the pharmacokinetics of the agent was investigated in a total of 9 patients, which included 1 neonate and 4 cases each of pre- and school age children. the Cmax, 4.85~8.83 μg/ml, was observed immediately after the termination of the instillation. the T 1/2's were 4.96 hours, 1.24~2.54 hours, and 1.78~1.88 hours in the neonate, the pre- and the school age children, respectively; in the neonate the half-life was longer. When 1.92~2.7 mg/kg were administered to 3 each of the pre- and school age children, urinary excretion rates in the first 6~8 hours were 40.1~56.5% of the dosages administered. in all cases, the urinary concentrations were highest in the first 2 hours, after the dministration, and then gradually decreased. These results suggest that arbekacin is a useful antibiotic for treating MRSA infections in the pediatric field.
AB - A clinical investigation was carried out to evaluate arbekacin, an aminoglycoside, in the treatment of MRS A infections (pneumonia, septicemia, etc.) of pediatric patients. the obtained results are summarized as follows. 1. Clinical results: Excluding those patients who met the present exclusion criteria and withdrawal cases from a total of 18 patients, 10 patients (3, 6, and 1 cases of septicemia, pneumonia, and urinary tract infection, respectively) were subjected to clinical evaluation. These were composed of 1, 1, 6, and 2 cases of neonate, infants, pre- and school age children, respectively. Excellent, good and fair results were obtained in 5, 2, and 3 patients, respectively; thus, the efficacy rate was 70.0%. the efficacy rate by disease was 100%, 50.0% and 100% in septicemia, pneumonia, and urinary tract infection, respectively. the bacteriological eradications were obtained in 70.0% of the total patients; by disease, these rates were 100% and 50.0% in septicemia/urinary tract infection and in pneumonia, respectively. the MIC50 as well as the MIC80 against MRS A strains isolated from 9 patients were 0.39 μg/ml and 1.56μg/ml, respectively. No adverse reactions were observed in the 15 patients, while in laboratory test values, one case each out of 12 patients examined showed 7-GTP elevation, proteinuria, and hematuria. 2. Pharmacokinetics: the pharmacokinetics of the agent was investigated in a total of 9 patients, which included 1 neonate and 4 cases each of pre- and school age children. the Cmax, 4.85~8.83 μg/ml, was observed immediately after the termination of the instillation. the T 1/2's were 4.96 hours, 1.24~2.54 hours, and 1.78~1.88 hours in the neonate, the pre- and the school age children, respectively; in the neonate the half-life was longer. When 1.92~2.7 mg/kg were administered to 3 each of the pre- and school age children, urinary excretion rates in the first 6~8 hours were 40.1~56.5% of the dosages administered. in all cases, the urinary concentrations were highest in the first 2 hours, after the dministration, and then gradually decreased. These results suggest that arbekacin is a useful antibiotic for treating MRSA infections in the pediatric field.
UR - http://www.scopus.com/inward/record.url?scp=0027958511&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027958511&partnerID=8YFLogxK
U2 - 10.11553/antibiotics1968b.47.57
DO - 10.11553/antibiotics1968b.47.57
M3 - Article
C2 - 8114274
AN - SCOPUS:0027958511
VL - 47
SP - 57
EP - 83
JO - The Journal of antibiotics. Ser. B
JF - The Journal of antibiotics. Ser. B
SN - 0368-2781
IS - 1
ER -